FR09C0054I2 - Derives de glp-1 - Google Patents

Derives de glp-1

Info

Publication number
FR09C0054I2
FR09C0054I2 FR09C0054C FR09C0054C FR09C0054I2 FR 09C0054 I2 FR09C0054 I2 FR 09C0054I2 FR 09C0054 C FR09C0054 C FR 09C0054C FR 09C0054 C FR09C0054 C FR 09C0054C FR 09C0054 I2 FR09C0054 I2 FR 09C0054I2
Authority
FR
France
Prior art keywords
glp
derivatives
analogues
action
pharmacological properties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR09C0054C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27221005&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR09C0054(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of FR09C0054I1 publication Critical patent/FR09C0054I1/fr
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of FR09C0054I2 publication Critical patent/FR09C0054I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
FR09C0054C 1996-08-30 2009-10-23 Derives de glp-1 Active FR09C0054I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK93196 1996-08-30
DK125996 1996-11-08
DK147096 1996-12-20
PCT/DK1997/000340 WO1998008871A1 (fr) 1996-08-30 1997-08-22 Derives de glp-1

Publications (2)

Publication Number Publication Date
FR09C0054I1 FR09C0054I1 (fr) 2009-04-12
FR09C0054I2 true FR09C0054I2 (fr) 2011-04-01

Family

ID=27221005

Family Applications (1)

Application Number Title Priority Date Filing Date
FR09C0054C Active FR09C0054I2 (fr) 1996-08-30 2009-10-23 Derives de glp-1

Country Status (21)

Country Link
EP (2) EP0944648B1 (fr)
JP (3) JP3149958B2 (fr)
KR (1) KR100556067B1 (fr)
CN (1) CN1271086C (fr)
AT (1) ATE356830T1 (fr)
BR (1) BRPI9711437B8 (fr)
CA (2) CA2468374C (fr)
CZ (1) CZ300837B6 (fr)
DE (3) DE69737479D1 (fr)
DK (1) DK0944648T3 (fr)
ES (1) ES2283025T3 (fr)
FR (1) FR09C0054I2 (fr)
HU (1) HU227021B1 (fr)
IL (3) IL128332A0 (fr)
NL (1) NL300422I2 (fr)
NO (3) NO325273B1 (fr)
PL (1) PL192359B1 (fr)
PT (1) PT944648E (fr)
RU (1) RU2214419C2 (fr)
UA (1) UA72181C2 (fr)
WO (1) WO1998008871A1 (fr)

Families Citing this family (478)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE417622T1 (de) 1996-08-08 2009-01-15 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
ATE356830T1 (de) * 1996-08-30 2007-04-15 Novo Nordisk As Glp-1 derivate
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
ATE466026T1 (de) * 1998-02-27 2010-05-15 Novo Nordisk As Derivate von glp-1 und exendin mit verlängertem wirkdauer-profil
JP2002508162A (ja) * 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ Ｎ末端を短縮したｇｌｐ−１誘導体
EP1062240B1 (fr) 1998-02-27 2010-04-28 Novo Nordisk A/S Derives de glp-1 modifies a l'extremite n-terminale
WO1999043708A1 (fr) * 1998-02-27 1999-09-02 Novo Nordisk A/S Derives de gpl-1 et de l'extendine au profil d'action etendu
DE69916811T2 (de) * 1998-02-27 2005-04-14 Novo Nordisk A/S Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
WO1999043706A1 (fr) 1998-02-27 1999-09-02 Novo Nordisk A/S Derives d'analogues de glp-1
WO1999046283A1 (fr) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Conjugues peptidiques pharmacologiquement actifs ayant une tendance reduite a l'hydrolyse enzymatique
ATE251465T1 (de) * 1998-07-31 2003-10-15 Novo Nordisk As In-vitro stimulation von beta zellen vermehrung
BR9913284A (pt) * 1998-08-28 2001-05-15 Lilly Co Eli Métodos para administrar peptìdeos insulinotrópicos
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
EP1666054A1 (fr) * 1998-08-28 2006-06-07 Eli Lilly & Company Méthode d' administration de peptides à activité insulinotropique
CA2343268A1 (fr) 1998-09-17 2000-03-23 Eli Lilly And Company Preparation a base de proteines
MY155270A (en) * 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
CN1495198A (zh) 1998-12-07 2004-05-12 �о���Ӧ�ÿ�ѧЭ��ɷ����޹�˾ 胰高血糖素样肽-1的类似物
AR021576A1 (es) * 1998-12-07 2002-07-24 Ipsen Pharma Sas Analogos del peptido 1-similar al glucagon, uso de los mismos para la manufactura de un medicamento y composiciones farmaceuticas que los contienen.
KR100458748B1 (ko) * 1998-12-07 2004-12-03 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 Ｇｌｐ-1 유사체
US6902744B1 (en) * 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
EP1163268B1 (fr) * 1999-03-15 2011-05-11 Novo Nordisk A/S Separation de glp-1 et de peptides associes par chromatographie d'echange d'ions
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
ATE409193T1 (de) 1999-03-17 2008-10-15 Novo Nordisk As Verfahren zur acylierung von peptiden und proteinen
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
KR20020002480A (ko) * 1999-03-17 2002-01-09 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 펩티드의 아실화법 및 신규한 아실화제
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
BR0010705A (pt) * 1999-04-30 2002-02-05 Amylin Pharmaceuticals Inc Exendinas modificadas e agonistas da exendina
DE60006100T2 (de) 1999-05-17 2004-07-01 Conjuchem, Inc., Montreal Lang wirkende insulinotrope peptide
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
EP1076066A1 (fr) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides abaissant le taux de glucose sanguin
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
AU1269501A (en) * 1999-11-12 2001-05-30 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
US6844321B2 (en) * 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
AU2001237254A1 (en) 2000-03-08 2001-09-17 Novo-Nordisk A/S Lowering serum lipids
DE10013895A1 (de) 2000-03-21 2001-10-04 Dmc2 Degussa Metals Catalysts Cerdec Ag Verfahren zur katalytischen Umsetzung von Kohlenmonoxid in einem Wasserstoff enthaltenden Gasgemisch
WO2002010195A2 (fr) * 2000-08-02 2002-02-07 Theratechnologies Inc. Peptides biologiques modifies presentant une activite renforcee
DE60136958D1 (de) 2000-12-01 2009-01-22 Takeda Pharmaceutical Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
KR100942864B1 (ko) * 2000-12-07 2010-02-17 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 융합 단백질
SK7822003A3 (en) 2000-12-21 2003-12-02 Aventis Pharma Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
DE50110906D1 (de) 2000-12-21 2006-10-12 Sanofi Aventis Deutschland Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
AU2002235731A1 (en) * 2001-03-07 2002-09-19 Novo Nordisk A/S Combined use of derivatives of glp-1 analogs and ppar ligands
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
DE10142660A1 (de) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
EP1385867B1 (fr) * 2001-05-02 2006-08-30 Novo Nordisk A/S Preparation d'acides biliaires
US6653492B2 (en) 2001-05-02 2003-11-25 Novo Nordick A/S Preparation of bile acids
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
US20030119734A1 (en) * 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
US20030082671A1 (en) 2001-07-24 2003-05-01 Thomas Hoeg-Jensen Method for making acylated polypeptides
RS11104A (en) 2001-08-22 2006-12-15 Sanofi Aventis Deutschland Gmbh. Combined preparations,containing 1,4- benzothiepine-1,1- dioxide derivatives and other active substances, and the use thereof
DE10142663B4 (de) 2001-08-31 2004-08-19 Aventis Pharma Deutschland Gmbh C2-Disubstituierte Indan-1-ol-Systeme
DE10142668A1 (de) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
EP1425014B1 (fr) 2001-08-31 2006-12-13 Sanofi-Aventis Deutschland GmbH Derives de diarylcycloalkyle, leur procede de production et leur utilisation en tant qu'activateurs des ppar
US6884812B2 (en) 2001-08-31 2005-04-26 Aventis Pharma Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
DE10142666A1 (de) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142662B4 (de) 2001-08-31 2004-07-08 Aventis Pharma Deutschland Gmbh Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel
DE10142722A1 (de) 2001-08-31 2003-03-27 Aventis Pharma Gmbh C2-substituierte Indan-1-one und ihre Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7399777B2 (en) 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10142661B4 (de) 2001-08-31 2004-06-09 Aventis Pharma Deutschland Gmbh Mehrfach substituierte Indan-1-ol-Systeme und ihre Verwendung als Arzneimittel
DE10142667B4 (de) 2001-08-31 2004-06-09 Aventis Pharma Deutschland Gmbh C2-substituierte Indan-1-ole und ihre Derivate und ihre Verwendung als Arzneimittel
DE10142659A1 (de) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von mehrfach substituierten Indan-1-ol. Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142665B4 (de) 2001-08-31 2004-05-06 Aventis Pharma Deutschland Gmbh C2-Disubstituierte Indan-1-one und ihre Derivate
IL160983A0 (en) 2001-09-24 2004-08-31 Imp College Innovations Ltd Use of pyy for preparation of a medicament for modification of feeding behavior
EP2243776A1 (fr) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Piperidines substituées et leur utilisation dans le traitement de maladies liées au recepteur histaminique H3
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
NZ531788A (en) * 2001-10-18 2008-01-31 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
AU2002351748B2 (en) 2001-12-21 2009-07-09 Novo Nordisk A/S Amide derivatives as GK activators
AU2002351752A1 (en) 2001-12-29 2003-07-30 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
AU2003200839B2 (en) * 2002-01-08 2008-12-11 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
CA2472882A1 (fr) * 2002-01-10 2003-07-17 Imperial College Innovations Ltd Utilisation de pyy et de glp-1, ou d'un antagoniste correspondant, pour la modification du comportement alimentaire
CN1332711C (zh) 2002-02-20 2007-08-22 埃米球科技有限公司 施用glp－1分子的方法
US7223796B2 (en) 2002-04-11 2007-05-29 Sanofi-Aventis Deutschland Gmbh Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
US7049341B2 (en) 2002-06-07 2006-05-23 Aventis Pharma Deutschland Gmbh N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use
US7671047B2 (en) 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176194B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176193B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
CA2744893A1 (fr) 2002-06-27 2004-01-08 Novo Nordisk A/S Derives d'arylcarbonyle servant d'activateurs de glucokinase
AU2003243929B2 (en) * 2002-07-04 2009-06-04 Zp Holding Spv K/S GLP-1 and methods for treating diabetes
US7262220B2 (en) 2002-07-11 2007-08-28 Sanofi-Aventis Deutschland Gmbh Urea- and urethane-substituted acylureas, process for their preparation and their use
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
BR0312697A (pt) 2002-07-12 2005-04-26 Aventis Pharma Gmbh Benzoiluréias substituìdas heterociclicamente, processo para a sua preparação e sua aplicação como medicamento
US7141561B2 (en) 2002-07-25 2006-11-28 Sanofi-Aventis Deutschland Gmbh Substituted diaryl heterocycles, process for their preparation and their use as medicaments
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US7067488B2 (en) 2002-09-25 2006-06-27 Theratechnologies Inc. Modified GLP-1 peptides with increased biological potency
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
PL210455B1 (pl) * 2002-09-25 2012-01-31 Novo Nordisk As Sposób otrzymywania acylowanych peptydów
US20040157922A1 (en) 2002-10-04 2004-08-12 Aventis Pharma Deutschland Gmbh Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
US7208504B2 (en) 2002-10-12 2007-04-24 Sanofi-Aventis Deutschland Gmbh Bicyclic inhibitors of hormone sensitive lipase
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
WO2004060387A1 (fr) 2002-12-27 2004-07-22 Diobex, Inc. Compositions et procedes de prevention et reduction de l'hypoglycemie induite par l'insuline
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US20040242583A1 (en) 2003-01-20 2004-12-02 Aventis Pharma Deutschland Gmbh Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
ATE502665T1 (de) 2003-02-04 2011-04-15 Novo Nordisk As Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
WO2004089470A2 (fr) 2003-04-11 2004-10-21 Novo Nordisk A/S Utilisation pharmaceutique d'amides substitues
US7390814B2 (en) 2003-02-13 2008-06-24 Sanofi-Aventis Deutschland Gmbh Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments
US7652007B2 (en) 2003-02-13 2010-01-26 Sanofi-Aventis Deutschland Gmbh Nitrogen-substituted hexahydropyrazino[1,2-A]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7501440B2 (en) 2003-03-07 2009-03-10 Sanofi-Aventis Deutschland Gmbh Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
WO2004078195A1 (fr) 2003-03-07 2004-09-16 Ajinomoto Co., Inc. Agent de conversion de cellule intestinale en cellule produisant de l'insuline et remede pour le diabete
BRPI0407936A (pt) 2003-03-19 2006-02-21 Lilly Co Eli composto de glp-1 peguilado, método de estimular o receptor de glp-1 em um indivìduo, e, uso de composto glp-1 peguilado
CN1816622B (zh) * 2003-03-28 2011-06-22 株式会社三和化学研究所 高产重组蛋白的植物贮藏器官的生产方法以及新型重组蛋白
DE10314610A1 (de) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
ES2737835T3 (es) 2003-04-23 2020-01-16 Valeritas Inc Bomba accionada hidráulicamente para la administración de medicamentos de larga duración
KR101308912B1 (ko) 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
WO2004105790A1 (fr) 2003-06-03 2004-12-09 Novo Nordisk A/S Compositions peptidiques pharmaceutiques stabilisees
AU2004266757A1 (en) 2003-08-21 2005-03-03 Novo Nordisk A/S Separation of polypeptides comprising a racemized amino acid
WO2005023291A2 (fr) * 2003-09-11 2005-03-17 Novo Nordisk A/S Utilisation d'agonistes de glp-i dans le traitement de patients souffrant de diabete de type i
CN101380476A (zh) * 2003-09-19 2009-03-11 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
WO2005046716A1 (fr) * 2003-11-13 2005-05-26 Novo Nordisk A/S Compositions pharmaceutiques solubles destinées à l'administration parentérale comprenant un peptide glp-1 et un peptide d'insuline à temps d'action de courte durée, utiles pour le traitement du diabète et de la boulimie
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
CN104826116A (zh) 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
JP4865565B2 (ja) 2003-12-09 2012-02-01 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストを用いた食物選択の制御
JP2007536214A (ja) * 2003-12-16 2007-12-13 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１類似体
AR047776A1 (es) 2003-12-16 2006-02-22 Sod Conseils Rech Applic Composiciones farmaceuticas glp - 1
WO2005058954A1 (fr) 2003-12-18 2005-06-30 Novo Nordisk A/S Nouveaux composes de glp-1
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
PL1723128T3 (pl) 2004-01-06 2013-04-30 Novo Nordisk As Pochodne heteroarylowe mocznika oraz ich zastosowanie jako aktywatory glukokinazy
WO2005066207A1 (fr) * 2004-01-08 2005-07-21 Theratechnologies Inc. Analogues peptidiques 1 semblables au glucagon a action de longue duree
JP4874811B2 (ja) 2004-01-21 2012-02-15 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ペプチドのトランスグルタミナーゼ媒介性の結合
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
US7402674B2 (en) 2004-01-31 2008-07-22 Sanofi-Aventis Deutschland Gmbh, 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7470706B2 (en) 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7498341B2 (en) 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004005172A1 (de) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
KR100564618B1 (ko) 2004-03-11 2006-03-28 삼성전자주식회사 디스크 드라이브의 층간 탐색 방법
EP1586573B1 (fr) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, procédé pour leur préparation, usage comme agents pharmaceutiques
GT200500063A (es) 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
EP1604988A1 (fr) 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Dérivés de pyridazinone, méthodes de leur préparation et leur utilisation comme pharmaceutiques
CN1950078A (zh) 2004-06-11 2007-04-18 诺和诺德公司 使用glp－1激动剂抵抗药物诱发的肥胖
WO2006014425A1 (fr) 2004-07-02 2006-02-09 Biovalve Technologies, Inc. Procedes et dispositifs pour l'administration du glp-1 et leurs utilisations
JP4965446B2 (ja) 2004-08-31 2012-07-04 ノヴォ ノルディスク アー／エス ペプチド、ポリペプチド及びタンパク質の安定化のためのトリス（ヒドロキシメチル）アミノメタンの使用
EP1841749A1 (fr) 2004-09-02 2007-10-10 Metabasis Therapeutics, Inc. Derives d'inhibiteurs de thiazole et de thiadiazoles de tyrosine phosphatases
JP5107713B2 (ja) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー／エス 遅延性のエキセンディン−４化合物
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１化合物
ES2458991T3 (es) 2004-11-12 2014-05-07 Novo Nordisk A/S Formulaciones estables de péptidos insulinotrópicos
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
CA2590720A1 (fr) 2004-12-03 2006-06-08 Lone Jeppesen Composes heteroaromatiques activants de glucokinase
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
ES2435522T3 (es) 2005-02-02 2013-12-20 Novo Nordisk A/S Derivados de insulina
WO2006082204A1 (fr) 2005-02-02 2006-08-10 Novo Nordisk A/S Derives d'insuline
EP1863521B1 (fr) 2005-03-18 2014-05-07 Novo Nordisk A/S Composes glp-1 avances
TWI362392B (en) * 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US8512288B2 (en) 2006-08-23 2013-08-20 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US8137314B2 (en) 2006-08-23 2012-03-20 Medtronic Minimed, Inc. Infusion medium delivery device and method with compressible or curved reservoir or conduit
US20080097291A1 (en) 2006-08-23 2008-04-24 Hanson Ian B Infusion pumps and methods and delivery devices and methods with same
US7905868B2 (en) 2006-08-23 2011-03-15 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US8840586B2 (en) 2006-08-23 2014-09-23 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US8277415B2 (en) 2006-08-23 2012-10-02 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US7955305B2 (en) 2005-05-06 2011-06-07 Medtronic Minimed, Inc. Needle inserter and method for infusion device
US20090227493A1 (en) * 2005-05-27 2009-09-10 Daiichi Sankyo Company, Limited Combined drug for treating diabetes
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
JP5052511B2 (ja) 2005-06-30 2012-10-17 ハイ ポイント ファーマシューティカルズ，エルエルシー Ｐｐａｒデルタ活性化因子としてのフェノキシ酢酸
EP2386554A1 (fr) 2005-07-04 2011-11-16 High Point Pharmaceuticals, LLC Composés actives sur le recepteur histamine H3
CA2615938C (fr) 2005-07-14 2014-04-29 Novo-Nordisk A/S Activateurs de l'uree glucokinase
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
SI1767545T1 (sl) * 2005-09-22 2010-03-31 Biocompatibles Uk Ltd GLP Glukagonu podobni peptidi fuzijski polipeptidi s povečano rezistenco na peptidazo
US8852164B2 (en) 2006-02-09 2014-10-07 Deka Products Limited Partnership Method and system for shape-memory alloy wire control
DK1951658T3 (da) 2005-11-17 2012-10-15 Lilly Co Eli Glucagonreceptorantagonister, fremstilling og terapeutiske anvendelser
JP5096363B2 (ja) * 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
NZ568488A (en) 2005-12-22 2011-07-29 High Point Pharmaceuticals Llc Phenoxy acetic acids as PPAR delta activators
DK1984009T3 (da) 2006-01-18 2013-01-28 Qps Llc Farmaceutiske sammensætninger med forbedret stabilitet
US11364335B2 (en) 2006-02-09 2022-06-21 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US11497846B2 (en) 2006-02-09 2022-11-15 Deka Products Limited Partnership Patch-sized fluid delivery systems and methods
US11027058B2 (en) 2006-02-09 2021-06-08 Deka Products Limited Partnership Infusion pump assembly
US11478623B2 (en) 2006-02-09 2022-10-25 Deka Products Limited Partnership Infusion pump assembly
JP5448460B2 (ja) 2006-02-09 2014-03-19 デカ・プロダクツ・リミテッド・パートナーシップ 医療装置のための接着による装置および方法、ならびに周辺の装置および方法
CA2645376C (fr) 2006-03-13 2017-06-20 Activx Biosciences, Inc. Aminoquinolones utilisees comme inhibiteurs de la gsk-3
ES2397659T3 (es) 2006-03-15 2013-03-08 Novo Nordisk A/S Mezclas de amilina e insulina
WO2007110364A1 (fr) 2006-03-28 2007-10-04 High Point Pharmaceuticals, Llc Benzothiazoles presentant une activité sur le récepteur h3 de l'histamine
ES2566058T3 (es) 2006-03-30 2016-04-08 Valeritas, Inc. Dispositivo de suministro de fluidos de múltiples cartuchos
ATE543798T1 (de) 2006-04-24 2012-02-15 Lilly Co Eli Cyclohexyl-substituierte pyrrolidinone als hemmer von 11-beta-hydroxysteroiddehydrogenase 1
DE602006009631D1 (de) 2006-05-10 2009-11-19 Biocompatibles Uk Ltd GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
EA016026B1 (ru) 2006-05-29 2012-01-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи 3-(1,3-бензодиоксол-5-ил)-6-(4-циклопропилпиперазин-1-ил)пиридазин, его соли и сольваты и его применение в качестве антагониста н3 рецептора гистамина
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
CN101511380B (zh) 2006-07-11 2012-12-12 昌达生物科技公司 用于持续释放递送肽的药物组合物
MX2009000748A (es) 2006-07-18 2009-03-31 Centocor Inc Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos.
EP2061767B1 (fr) 2006-08-08 2014-12-17 Sanofi Imidazolidin-2,4-diones arylaminoaryl-alkyl-substituées, procédé de fabrication, médicaments les contenant et leur utilisation
US7828764B2 (en) 2006-08-23 2010-11-09 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US7789857B2 (en) 2006-08-23 2010-09-07 Medtronic Minimed, Inc. Infusion medium delivery system, device and method with needle inserter and needle inserter device and method
US7811262B2 (en) 2006-08-23 2010-10-12 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US7794434B2 (en) 2006-08-23 2010-09-14 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US20100056428A1 (en) 2006-09-01 2010-03-04 Novo Nordisk Health Care Ag Modified proteins
AU2007293885A1 (en) 2006-09-07 2008-03-13 Takeda Gmbh Combination treatment for diabetes mellitus
US8022066B2 (en) 2006-11-15 2011-09-20 High Point Pharmaceuticals, Llc 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
AU2008204530B2 (en) 2007-01-11 2013-08-01 Vtv Therapeutics Llc Urea glucokinase activators
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
EP1975176A1 (fr) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Nouveaux peptides à fusion GLP-1, leur production et utilisation
US8434528B2 (en) 2007-04-30 2013-05-07 Medtronic Minimed, Inc. Systems and methods for reservoir filling
EP2146760B1 (fr) 2007-04-30 2018-10-10 Medtronic MiniMed, Inc. Remplissage de réservoir, gestion des bulles d'air, et systèmes et procédés d'administration de milieu de perfusion associés
US8597243B2 (en) 2007-04-30 2013-12-03 Medtronic Minimed, Inc. Systems and methods allowing for reservoir air bubble management
US7963954B2 (en) 2007-04-30 2011-06-21 Medtronic Minimed, Inc. Automated filling systems and methods
US8613725B2 (en) 2007-04-30 2013-12-24 Medtronic Minimed, Inc. Reservoir systems and methods
US7959715B2 (en) 2007-04-30 2011-06-14 Medtronic Minimed, Inc. Systems and methods allowing for reservoir air bubble management
US8323250B2 (en) 2007-04-30 2012-12-04 Medtronic Minimed, Inc. Adhesive patch systems and methods
WO2008149345A2 (fr) 2007-06-04 2008-12-11 Ben-Gurion University Of The Negev Research And Development Authority Composés triarylés et compositions les comprenant
US20080319221A1 (en) 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
JP2009019027A (ja) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
CN101743252A (zh) 2007-07-16 2010-06-16 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、peg化的胰岛素类似物
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
WO2009030774A1 (fr) * 2007-09-05 2009-03-12 Novo Nordisk A/S Dérivés glp-1 tronqués et utilisations à des fins thérapeutiques de ceux-ci
CN101842109B (zh) 2007-09-05 2014-01-29 诺沃-诺迪斯克有限公司 用a-b-c-d-衍生的肽和它们的治疗用途
CN101868476B (zh) 2007-09-05 2015-02-25 诺沃-诺迪斯克有限公司 胰高血糖素样肽-1衍生物及其制药用途
ATE531721T1 (de) 2007-09-11 2011-11-15 Kyorin Seiyaku Kk Cyanoaminochinolone als gsk-3-inhibitoren
MX2010002662A (es) 2007-09-12 2010-04-09 Activx Biosciences Inc Aminoquinolonas espirociclicas como inhibidores de gsk-3.
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
BRPI0820535B8 (pt) 2007-11-16 2021-05-25 Novo Nordisk As composições farmacêuticas contendo insulina e um peptídeo insulinotrópico
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
US8881774B2 (en) 2007-12-31 2014-11-11 Deka Research & Development Corp. Apparatus, system and method for fluid delivery
US10188787B2 (en) 2007-12-31 2019-01-29 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
US8900188B2 (en) 2007-12-31 2014-12-02 Deka Products Limited Partnership Split ring resonator antenna adapted for use in wirelessly controlled medical device
US10080704B2 (en) 2007-12-31 2018-09-25 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
CN101959547B (zh) 2007-12-31 2014-11-26 德卡产品有限公司 输注泵组件
EP3679969A3 (fr) 2007-12-31 2020-09-30 DEKA Products Limited Partnership Ensemble pompe à perfusion
US9456955B2 (en) 2007-12-31 2016-10-04 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008025007A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
CN101970476B (zh) 2008-01-09 2014-08-27 塞诺菲-安万特德国有限公司 具有超延迟时效特征的胰岛素衍生物
EP2229407B1 (fr) 2008-01-09 2016-11-16 Sanofi-Aventis Deutschland GmbH Nouveaux dérivés d'insuline à profil temporel/d'action extrêmement retardé
EP2259791A2 (fr) * 2008-03-05 2010-12-15 Tel HaShomer Medical Research Infrastructure and Services Ltd. Agonistes du récepteur glp-1 et ingrédients pharmaceutiques actifs apparentés pour le traitement du cancer
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
CN101555214B (zh) 2008-04-08 2012-07-11 北京嘉事联博医药科技有限公司 苯基环丁基酰胺衍生物及其光学异构体、制备方法和用途
EP2926825A1 (fr) 2008-06-27 2015-10-07 Duke University Agents thérapeutiques comprenant des peptides de type élastine
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
US8865868B2 (en) 2008-08-06 2014-10-21 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy
US8637647B2 (en) 2008-09-12 2014-01-28 Novo Nordisk A/S Method of acylating a peptide or protein
CA3037726C (fr) 2008-09-15 2021-11-16 Deka Products Limited Partnership Systemes et procedes de distribution de fluides
DE102008053048A1 (de) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008051834A1 (de) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
DE102009038210A1 (de) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
US8889618B2 (en) 2008-11-07 2014-11-18 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (GLP-1)
IT1392655B1 (it) 2008-11-20 2012-03-16 Bio Ker S R L Site-specific monoconjugated insulinotropic glp-1 peptides.
EA020496B1 (ru) 2008-11-21 2014-11-28 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Производное адамантилбензамида, фармацевтическая композиция, включающая его, и его применение
CN102307904A (zh) 2008-12-05 2012-01-04 安吉奥开米公司 神经降压素或神经降压素类似物的缀合物及其用途
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
ES2439499T3 (es) 2008-12-15 2014-01-23 Zealand Pharma A/S Análogos de glucagón
AU2008365556A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
MX2011006315A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
CA2747109A1 (fr) 2008-12-15 2010-06-24 Zealand Pharma A/S Analogues du glucagon
AU2010207725B2 (en) 2009-01-22 2015-06-11 Novo Nordisk Health Care Ag Stable growth hormone compounds
US9480753B2 (en) 2009-01-23 2016-11-01 Novo Nordisk A/S FGF21 derivatives with albumin binder A-B-C-D-E- and their use
CN101824087A (zh) * 2009-03-05 2010-09-08 连云港恒邦医药科技有限公司 胰高血糖素样肽-2类似物及其制备方法和用途
EP2406266B1 (fr) 2009-03-11 2013-12-25 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones comme inhibiteurs de la gsk-3
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
AU2010256366B2 (en) * 2009-06-05 2014-08-21 Veroscience, Llc Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders
AU2014265118B2 (en) * 2009-06-05 2016-11-17 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders
US20120172298A1 (en) * 2009-06-11 2012-07-05 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
EA022816B1 (ru) 2009-07-13 2016-03-31 Зилэнд Фарма А/С Ацилированные аналоги глюкагона
EP2453948B1 (fr) 2009-07-15 2015-02-18 DEKA Products Limited Partnership Appareil, systèmes et procédés pour un ensemble pompe à perfusion
CN101987868B (zh) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
US8614182B2 (en) 2009-07-30 2013-12-24 Jiangsu Hansoh Pharmaceuticals Co., Ltd. GLP-1 analogues and their pharmaceutical salts and uses
JP6086528B2 (ja) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有する成長ホルモン
RU2012111354A (ru) 2009-08-26 2013-10-10 Санофи Новые кристаллические гидраты фторгликозидов, содержащие их фармацевтические препараты и их использование
BR112012007349A2 (pt) 2009-10-02 2019-09-24 Sanofi Sa uso de composto com atividade inibidora de sglt-1/sglt-2 para produção de medicamentos para tratamento de doenças ósseas.
EP2491054A2 (fr) 2009-10-22 2012-08-29 Cadila Healthcare Limited Antagoniste des récepteurs du glucagon et agoniste du glp-i actifs par voie orale, à base de peptidomimétiques à chaîne courte
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
TWI484974B (zh) 2009-12-16 2015-05-21 Novo Nordisk As 雙重醯化ｇｌｐ－１衍生物
BR112012018162A2 (pt) 2010-01-22 2017-10-03 Novo Nordisk Healthcare Ag Compostos de hormônio do crescimento estáveis
BR112012018116B1 (pt) 2010-01-22 2022-06-21 Novo Nordisk Health Care Ag Conjugados de hormônio do crescimento com eficácia in vivo prolongada
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
EP2539364A1 (fr) 2010-02-26 2013-01-02 Novo Nordisk A/S Peptides de traitement de l'obésité
US9422330B2 (en) * 2010-03-01 2016-08-23 Novo Nordisk A/S Preparative RP-HPLC method for purifying peptides
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EP2552951A1 (fr) 2010-03-26 2013-02-06 Novo Nordisk A/S Nouveaux analogues du glucagon
EP2555791B1 (fr) 2010-04-09 2017-11-01 Sinai Health System Méthodes de traitement de troubles du tractus gastro-intestinal au moyen d'un agoniste glp-1
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
KR20130098873A (ko) 2010-04-27 2013-09-05 질랜드 파마 에이/에스 Glp-1 수용체 작용제 및 가스트린의 펩타이드 접합체 및 그의 용도
JP5827218B2 (ja) 2010-04-30 2015-12-02 株式会社三和化学研究所 生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
WO2011157827A1 (fr) 2010-06-18 2011-12-22 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
SG186764A1 (en) 2010-06-24 2013-02-28 Zealand Pharma As Glucagon analogues
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
BR112013004756B1 (pt) 2010-08-30 2020-04-28 Sanofi Aventis Deutschland uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
WO2012061466A2 (fr) 2010-11-02 2012-05-10 The General Hospital Corporation Méthodes de traitement d'une maladie de stéatose
ES2683372T3 (es) 2010-11-09 2018-09-26 Novo Nordisk A/S Derivados de GLP-1 acilados con un conector nuevo
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
CN103298456A (zh) 2011-01-19 2013-09-11 诺沃—诺迪斯克有限公司 Glp-1颗粒和组合物
WO2012098187A1 (fr) 2011-01-19 2012-07-26 Novo Nordisk A/S Compositions de glp-1
JP2014504597A (ja) 2011-01-20 2014-02-24 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体とインスリン類似体の組合せ物
US10130684B2 (en) 2011-02-03 2018-11-20 Pharmedica Ltd. Oral dissolving films for insulin administration, for treating diabetes
EP2683698B1 (fr) 2011-03-08 2017-10-04 Sanofi Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
EP2683700B1 (fr) 2011-03-08 2015-02-18 Sanofi Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
EP2683702B1 (fr) 2011-03-08 2014-12-24 Sanofi Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683703B1 (fr) 2011-03-08 2015-05-27 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
WO2012120053A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
EP2683705B1 (fr) 2011-03-08 2015-04-22 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US20140031278A1 (en) 2011-03-28 2014-01-30 Novo Nordisk A/S Novel Glucagon Analogues
EP3225631B1 (fr) * 2011-04-12 2019-01-09 Novo Nordisk A/S Dérivés glp-1 double-acylates
WO2012150503A2 (fr) 2011-05-03 2012-11-08 Zealand Pharma A/S Composés sélectifs de la signalisation d'agoniste mixte glu-glp-1
EP2707713A2 (fr) 2011-05-10 2014-03-19 Zealand Pharma A/S Composés sélectifs pour une signalisation d'agonistes doubles de glu-glp1
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2729157B1 (fr) 2011-07-06 2019-01-16 The General Hospital Corporation Un pentapeptide dérivé de l'extrémité c-terminale du glp-1 (glucagon-like peptide 1) pour le traitement
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN103189389B (zh) * 2011-09-03 2017-08-11 深圳市健元医药科技有限公司 新的glp‑ⅰ类似物及其制备方法和用途
CN107266558A (zh) * 2011-09-06 2017-10-20 诺沃—诺迪斯克有限公司 Glp‑1衍生物
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
BR112014006684A2 (pt) 2011-09-23 2017-03-28 Novo Nordisk As análogos de glucagon
TW201315742A (zh) 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
EP2763691A1 (fr) 2011-10-04 2014-08-13 Sanofi-Aventis Deutschland GmbH Agoniste du glp-1 pour l'utilisation dans le traitement de la sténose et/ou de l'obstruction dans le tractus biliaire
EP2763690B1 (fr) 2011-10-04 2015-11-25 Sanofi-Aventis Deutschland GmbH Lixisenatide pour l'utilisation dans le traitement de la sténose et/ou de l'obstruction dans le système des conduits pancréatiques
AR088636A1 (es) 2011-11-03 2014-06-25 Zealand Pharma As Conjugados peptidicos de un agonista del receptor de glp-1 y gastrina
JP2015500823A (ja) 2011-12-09 2015-01-08 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト
MX354156B (es) 2011-12-29 2018-02-15 Novo Nordisk As Dipeptido que comprende un aminoacido no proteogenico.
PL2814844T3 (pl) 2012-02-15 2017-12-29 Novo Nordisk A/S Przeciwciała wiążące i blokujące receptor aktywujący wykazujący ekspresję na komórkach szpikowych -1 (trem-1)
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
RS57827B1 (sr) 2012-02-15 2018-12-31 Novo Nordisk As Antitela koja vezuju protein 1 prepoznavanja peptidoglikana
US11524151B2 (en) 2012-03-07 2022-12-13 Deka Products Limited Partnership Apparatus, system and method for fluid delivery
ES2965469T3 (es) 2012-03-22 2024-04-15 Novo Nordisk As Composiciones que comprenden un agente de suministro y preparación de estas
ES2952874T3 (es) 2012-03-22 2023-11-06 Novo Nordisk As Composiciones de péptidos GLP-1 y preparación de estas
EP2844670B1 (fr) 2012-05-03 2017-12-06 Zealand Pharma A/S Analogues du glucagon-like peptide 2 (glp-2)
SG11201407137PA (en) 2012-05-03 2014-11-27 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
JP6250034B2 (ja) * 2012-05-08 2017-12-20 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
CN104411322B (zh) * 2012-05-08 2017-05-24 诺和诺德股份有限公司 双酰化glp‑1衍生物
EP2664374A1 (fr) * 2012-05-15 2013-11-20 F. Hoffmann-La Roche AG Dérivés de dipeptide d'acide lysine-glutamique
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
WO2014005858A1 (fr) 2012-07-01 2014-01-09 Novo Nordisk A/S Utilisation de peptides glp-1 à action longue
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
CN104662038B (zh) 2012-07-23 2018-11-06 西兰制药公司 胰高血糖素类似物
FR2994848B1 (fr) 2012-08-30 2014-08-22 Univ Paris Curie Traitement de l'arthrose par les hormones incretines ou leurs analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EP2908844A1 (fr) 2012-10-17 2015-08-26 Novo Nordisk A/S Acides aminés acylés par un acide gras pour l'administration de peptides par voie orale
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
US9867869B2 (en) 2012-12-12 2018-01-16 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
AR094181A1 (es) 2012-12-21 2015-07-15 Sanofi Sa Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon
CN103059127B (zh) * 2013-01-07 2014-12-17 天津嘉宏科技有限公司 Glp-1类似物及其制备方法与应用
CN105007931B (zh) 2013-03-01 2018-04-06 瓦尔德西布伦大学医院基金会研究所 肽在视网膜神经退行性疾病，特别是在糖尿病视网膜病变早期和神经退行性变起重要作用的其它视网膜疾病的局部治疗中的应用
HUE057168T2 (hu) 2013-03-15 2022-04-28 Protagonist Therapeutics Inc A hepcidin analógjai és ezek alkalmazása
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
CN105307672B (zh) 2013-04-18 2021-01-05 诺和诺德股份有限公司 用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂
EP4309699A3 (fr) 2013-07-03 2024-04-24 DEKA Products Limited Partnership Appareil et système de distribution de fluide
US10266577B2 (en) 2013-08-15 2019-04-23 Novo Nordisk A/S GLP-1 derivatives, and uses thereof
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
MY176022A (en) 2013-10-17 2020-07-21 Boehringer Ingelheim Int Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
US10111880B2 (en) 2013-11-05 2018-10-30 Ben-Gurion University Of The Negev Research And Development Authority Compounds for the treatment of diabetes and disease complications arising from same
TR201902516T4 (tr) 2013-11-06 2019-03-21 Zealand Pharma As Glukagon-glp-1-gıp üçlü agonist bileşikleri.
KR102310389B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 Ｇｉｐ-ｇｌｐ-1 이원 효능제 화합물 및 방법
EP3080150B1 (fr) 2013-12-13 2018-08-01 Sanofi Analogues peptidiques d'exendine-4 en tant qu'agonistes du récepteur gip/glp-1 double
EP3080154B1 (fr) 2013-12-13 2018-02-07 Sanofi Agonistes doubles du récepteur glp-1/gip
EP3080152A1 (fr) 2013-12-13 2016-10-19 Sanofi Analogues peptidiques de l'exendine 4 non acylés
WO2015086733A1 (fr) 2013-12-13 2015-06-18 Sanofi Agonistes mixtes des récepteurs du glp-1/glucagon
CN103884846B (zh) * 2014-03-06 2016-06-08 杭州九源基因工程有限公司 一种利拉鲁肽生物学活性的检测方法
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
EP3129041B1 (fr) * 2014-04-07 2019-06-12 Novo Nordisk A/S Composés glp-1 acylés doubles
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US10105442B2 (en) 2014-05-07 2018-10-23 Novo Nordisk A/S Treatment of diabetes type 1 using GLP-1 and anti-IL-21
SI3143037T1 (sl) 2014-05-16 2021-11-30 Protagonist Therapeutics, Inc. Antagonisti integrin alpha4beta7 tioeterskih peptidov
CN106536547A (zh) 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104987383A (zh) * 2014-07-08 2015-10-21 四川百利药业有限责任公司 一种glp-1衍生物
GB2528436A (en) 2014-07-15 2016-01-27 Lancaster Univ Business Entpr Ltd Treatment of neurological diseases
US9624268B2 (en) 2014-07-17 2017-04-18 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
CN106536559B (zh) 2014-07-17 2021-04-27 诺和诺德股份有限公司 定点诱变trem-1抗体以降低黏度
EP3530671A3 (fr) 2014-09-05 2019-11-13 University of Copenhagen Analogues de peptide gip
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
SG11201702553RA (en) 2014-10-01 2017-04-27 Protagonist Therapeutics Inc NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
DK3212218T3 (da) 2014-10-29 2021-08-30 Zealand Pharma As GIP-agonistforbindelser og fremgangsmåder
EP3226906B1 (fr) 2014-11-27 2019-06-12 Novo Nordisk A/S Dérivés glp-1 et leurs utilisations
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
KR102427527B1 (ko) 2014-12-23 2022-08-01 노보 노르디스크 에이/에스 Fgf21 유도체 및 그것의 용도
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
EP3271381B1 (fr) 2015-03-18 2021-09-08 Zealand Pharma A/S Analogues d'amyline
EP3273981B1 (fr) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Procédé et composition pharmaceutique pour une utilisation dans le traitement du diabète
CN107636010B (zh) * 2015-04-16 2021-10-01 西兰制药公司 酰化胰高血糖素类似物
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2016335287A1 (en) 2015-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
WO2017117411A1 (fr) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues de mimétiques d'hepcidine à demi-vie in vivo améliorée
EP3196206A1 (fr) 2016-01-20 2017-07-26 Lonza Ltd Procédé de préparation de liraglutide
US11236123B2 (en) 2016-01-20 2022-02-01 Polypeptide Laboratories Holding (Ppl) Ab Method for preparation of peptides with psWang linker
EP3205660A1 (fr) 2016-02-10 2017-08-16 Polypeptide Laboratories Holding (PPL) AB Procédé de préparation de peptides à liaison pswang
EP3205664A1 (fr) 2016-02-11 2017-08-16 Polypeptide Laboratories Holding (PPL) AB Procédé de préparation de liraglutide utilisant un lieur bal
WO2017149070A1 (fr) 2016-03-03 2017-09-08 Novo Nordisk A/S Dérivés de glp-1 et utilisations correspondantes
CN108883159A (zh) 2016-03-04 2018-11-23 诺和诺德股份有限公司 用于糖尿病性足溃疡的利拉鲁肽
MA43684A (fr) 2016-03-04 2018-11-28 Novo Nordisk As Liraglutide utilisé dans le traitement de maladies rénales
US10690635B2 (en) 2016-03-23 2020-06-23 Bachem Holding Ag Purification of glucagon-like peptide 1 analogs
CN109641946A (zh) 2016-03-23 2019-04-16 巴切姆股份公司 胰高血糖素样肽的制备方法
EP3432906A4 (fr) 2016-03-23 2020-04-01 Protagonist Therapeutics, Inc. Procédés de synthèse d'antagonistes de peptide alpha4beta7
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
US20190224122A1 (en) 2016-09-23 2019-07-25 Delpor, Inc. Stable compositions for incretin mimetic compounds
WO2018065634A1 (fr) 2016-10-07 2018-04-12 Cyprumed Gmbh Compositions pharmaceutiques pour l'administration par voie nasale de médicaments de type peptide ou protéine
JP7193455B2 (ja) 2016-11-28 2022-12-20 ノヴォ ノルディスク アー／エス 心血管状態におけるインスリンデグルデク
CN110099719A (zh) 2016-11-28 2019-08-06 诺和诺德股份有限公司 用于改善血糖控制以及减少急性和长期糖尿病并发症的德谷胰岛素
WO2018096164A1 (fr) 2016-11-28 2018-05-31 Novo Nordisk A/S Insuline dégludec pour le traitement du diabète
US11285180B2 (en) 2016-12-06 2022-03-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
WO2018103868A1 (fr) 2016-12-09 2018-06-14 Zealand Pharma A/S Agonistes doubles de glp-1/glp-2 acylés
RU2756011C2 (ru) 2016-12-09 2021-09-24 Зилэнд Фарма А/С Glp-1/glp-2 двойные агонисты
WO2018104558A1 (fr) 2016-12-09 2018-06-14 Zealand Pharma A/S Agonistes doubles de glp-1/glp-2 acylés
CA3043151A1 (fr) 2016-12-09 2018-06-14 Zealand Pharma A/S Agonistes doubles de glp-1/glp-2 acyles
GB201621987D0 (en) 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
US20200223889A1 (en) 2017-03-15 2020-07-16 Novo Nordisk A/S Bicyclic Compounds Capable of Binding to Melanocortin 4 Receptor
WO2018210919A1 (fr) 2017-05-17 2018-11-22 Novo Nordisk A/S Compositions de glp-1 et leurs utilisations
AU2018276434B2 (en) 2017-05-31 2021-12-16 University Of Copenhagen Long-acting GIP peptide analogues
CN111050750A (zh) 2017-08-24 2020-04-21 诺沃挪第克公司 Glp-1组合物及其用途
WO2019048660A1 (fr) 2017-09-10 2019-03-14 Novo Nordisk A/S Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité
WO2019051494A1 (fr) 2017-09-11 2019-03-14 Protagonist Therapeutics, Inc. Peptides d'agoniste opioïde et leurs utilisations
JP2021514936A (ja) 2017-12-19 2021-06-17 ノヴォ ノルディスク アー／エス Ｇｌｐ−１ペプチドの可溶性
MX2020007598A (es) 2018-02-02 2020-09-03 Novo Nordisk As Composiciones solidas que comprenden un agonista del peptido similar al glucagon tipo 1 (glp-1), una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante.
CA3089868A1 (fr) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Mimetiques d'hepcidine conjugues
SG11202008177WA (en) 2018-02-27 2020-09-29 Zp Spv 3 K/S Compstatin analogues and their medical uses
CR20200450A (es) 2018-04-02 2021-02-11 Bristol Myers Squibb Co Anticuerpos anti-trem-l y usos de los mismos
PE20211417A1 (es) 2018-04-05 2021-08-02 Sun Pharmaceutical Ind Ltd Analogos novedosos de glp-1
US20210087250A1 (en) 2018-04-06 2021-03-25 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
WO2019200594A1 (fr) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 Dérivé de glp-1 acylé
CA3098372A1 (fr) 2018-04-24 2019-10-31 Deka Products Limited Partnership Appareil et systeme pour la distribution de fluide
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
TW201946930A (zh) * 2018-05-15 2019-12-16 展旺生命科技股份有限公司 製備利拉魯肽衍生物的方法
US20210221867A1 (en) 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
US10905738B2 (en) 2018-07-05 2021-02-02 Biozeus Desenvolvimento De Produtos Biofarmacêuticos Synthetic peptides, prodrugs, pharmaceutical compositions and uses
WO2020053414A1 (fr) 2018-09-14 2020-03-19 Novo Nordisk A/S Composés bicycliques aptes à se lier aux agonistes du récepteur de la mélanocortine 4
BR112021010447A2 (pt) 2018-12-03 2021-08-24 Antag Therapeutics Aps Análogos de peptídeos gip modificados
EP3938037A1 (fr) 2019-03-15 2022-01-19 Diet4Life ApS Combinaison de peptides alimentaires
MA55504A (fr) 2019-04-01 2022-02-09 Novo Nordisk As Anticorps dirigés contre le liraglutide et leur utilisation
EP3997105A4 (fr) 2019-07-10 2023-09-13 Protagonist Therapeutics, Inc. Inhibiteurs peptidiques du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
BR112022003760A2 (pt) 2019-08-27 2022-05-31 Zp Spv 3 K/S Análogos de compstatina e seus usos médicos
EP4054620A1 (fr) 2019-11-06 2022-09-14 Novo Nordisk A/S Agonistes du récepteur glp-1 dans la démence
US20220395559A1 (en) 2019-11-07 2022-12-15 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2021105393A1 (fr) 2019-11-29 2021-06-03 Novo Nordisk A/S Procédés d'obtention de compositions de glp-1 stables
CN111040022B (zh) 2019-12-23 2021-12-14 万新医药科技(苏州)有限公司 针对胰高血糖素样肽-1受体、胰高血糖素受体、以及抑胃肽受体的三重激动剂
AU2020418207A1 (en) 2019-12-30 2022-08-25 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting GLP-1 compound
MX2022008741A (es) 2020-01-15 2022-10-03 Janssen Biotech Inc Inhibidores de peptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
KR20220143036A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 약학적 제형
EP4126003A1 (fr) 2020-03-30 2023-02-08 Zealand Pharma A/S Agonistes doubles de glp-1/glp-2
WO2021198195A1 (fr) 2020-03-30 2021-10-07 Zealand Pharma A/S Combinaison d'agonistes
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
JP2023524695A (ja) 2020-04-29 2023-06-13 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬およびヒスチジンを含む固形組成物
EP4146221A1 (fr) 2020-05-07 2023-03-15 Frederiksberg Hospital Traitement de l'hyperuricémie
EP4210680A1 (fr) 2020-09-07 2023-07-19 Cyprumed GmbH Formulations pharmaceutiques améliorées d'agonistes du récepteur glp-1
JP2023545684A (ja) 2020-09-30 2023-10-31 ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド ポリペプチドコンジュゲートおよび使用の方法
KR20230110570A (ko) 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. 인터류킨-23 수용체의 펩티드 억제제의 조성물
WO2022157548A1 (fr) 2021-01-24 2022-07-28 Forrest Michael David Inhibiteurs d'utilisations cosmétiques et thérapeutiques d'atp synthase
FR3120189A1 (fr) 2021-03-01 2022-09-02 Farid Bennis Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1
WO2023285334A1 (fr) 2021-07-12 2023-01-19 Novo Nordisk A/S Nouveaux dérivés d'urocortine 2 modifiés par un acide gras et leurs utilisations
WO2023012263A1 (fr) 2021-08-04 2023-02-09 Novo Nordisk A/S Formulations solides de peptides oraux
AU2022339044A1 (en) 2021-09-03 2024-03-14 Zealand Pharma A/S Dosage regime
WO2023038039A1 (fr) 2021-09-08 2023-03-16 塩野義製薬株式会社 Médicament destiné à la prévention et au traitement de maladies liées à l'activité anti-obésité
WO2023192873A1 (fr) * 2022-03-28 2023-10-05 Bristol-Myers Squibb Company Immunomodulateurs macrocycliques
WO2024061919A1 (fr) 2022-09-19 2024-03-28 Zealand Pharma A/S Polythérapie
WO2024068848A1 (fr) 2022-09-28 2024-04-04 Zealand Pharma A/S Méthodes de traitement de l'obésité
EP4345104A1 (fr) 2022-09-30 2024-04-03 Bachem Holding AG Procédé de préparation de liraglutide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1341320C (fr) 1986-05-05 2001-11-20 Joel Habener Hormone insulinotrope
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
ES2113879T3 (es) * 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
DK36492D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
ATE356830T1 (de) * 1996-08-30 2007-04-15 Novo Nordisk As Glp-1 derivate

Also Published As

Publication number Publication date
JP3149958B2 (ja) 2001-03-26
NL300422I2 (nl) 2010-04-01
NO990950L (no) 1999-04-28
IL189136A0 (en) 2008-06-05
CA2264243A1 (fr) 1998-03-05
HUP9903714A2 (hu) 2000-03-28
BR9711437A (pt) 2000-01-18
JP2001011095A (ja) 2001-01-16
FR09C0054I1 (fr) 2009-04-12
AU732957B2 (en) 2001-05-03
DE122009000079I1 (de) 2010-05-27
KR100556067B1 (ko) 2006-03-07
BRPI9711437B1 (pt) 2017-05-16
PL192359B1 (pl) 2006-10-31
NO2009027I1 (no) 2009-11-30
IL189136A (en) 2015-05-31
DE69737479T2 (de) 2007-11-29
EP0944648B1 (fr) 2007-03-14
DK0944648T3 (da) 2007-07-02
UA72181C2 (uk) 2005-02-15
NO990950D0 (no) 1999-02-26
EP1826216A1 (fr) 2007-08-29
EP0944648A1 (fr) 1999-09-29
CZ62999A3 (cs) 1999-07-14
DE69737479D1 (de) 2007-04-26
AU3847897A (en) 1998-03-19
ES2283025T3 (es) 2007-10-16
NL300422I1 (nl) 2010-01-04
JP2000500505A (ja) 2000-01-18
KR20000035964A (ko) 2000-06-26
NO325273B1 (no) 2008-03-17
PL331896A1 (en) 1999-08-16
ATE356830T1 (de) 2007-04-15
PT944648E (pt) 2007-06-26
CA2468374A1 (fr) 1998-03-05
CN1232470A (zh) 1999-10-20
RU2214419C2 (ru) 2003-10-20
CA2264243C (fr) 2004-10-05
IL128332A0 (en) 2000-01-31
CN1271086C (zh) 2006-08-23
CA2468374C (fr) 2010-12-21
NO2009027I2 (no) 2015-01-19
JP2006348038A (ja) 2006-12-28
DE122009000079I2 (de) 2011-06-16
BRPI9711437B8 (pt) 2021-05-25
WO1998008871A1 (fr) 1998-03-05
HU227021B1 (en) 2010-05-28
NO2019036I1 (no) 2019-09-20
AU732957C (en) 1998-03-19
IL128332A (en) 2008-04-13
HUP9903714A3 (en) 2000-07-28
CZ300837B6 (cs) 2009-08-26
DE69737479T4 (de) 2010-05-06

Similar Documents

Publication Publication Date Title
NO2019036I1 (no) Liraglutid - forlenget SPC
IT1266582B1 (it) Derivati (di)azacicloesanici e diazacicloeptanici
NL350021I1 (nl) 3-Aryl-4-hydroxy-delta3-dihydrofuranon- en 3-aryl-4-hydroxy-delta3-dihydrothiofenon-derivaten.
DK0593585T3 (da) Peptid, som modvirker TNF- og LPS-toksicitet
KR960703888A (ko) 이소플라본 유도체 (isoflavone derivatives)
NO20001939L (no) Sulfonert, i det vesentlige randomisert interpolymer, blandinger derav og gjenstander fremstilt derav
FR2772814B1 (fr) Voute gonflable, deployable et escamotable
ITMI911520A0 (it) Derivati di piperidina, loro preparazione e uso
TR28331A (tr) 13-ikameli milbemisin türevleri, bunlarin hazirlanmalari ve kullanimlari.
IT8919964A0 (it) Proteine inibenti i ribosomi e loro derivati.
TR199700354A3 (tr) Karbohidrat türevleri.
IT8919113A0 (it) Sci bipattino ripiegabile.
ITMI941191A0 (it) 1-b-metil-2-tiol carbapen derivati
NO903229D0 (no) Substituerte isoksazol- og isotiazolderivater.
ITRM950542A0 (it) Azocoloranti e mediatori, loro produzione ed uso. (caso 158-5805)
ATE199901T1 (de) 10,11-dihydro-10-oxo-5h-dibenz(b,f)azepin-5- carboxamidderivate
ITTO920606A1 (it) Derivati di decaidro-8h-isochino/2, 1-g/1, 6/naftiridina e decaidrobenzo /a/pirrolo/2, 3-e/chinolizina.
IT8921746V0 (it) Porta da calcio gonfiabile.
MX24407A (es) (1)benzopirano(4,3-c)-pirazoles y procedimiento para su preparacion.
DK1042291T3 (da) Arylsubstituerede pyridylalkan-, alken- og alkyncarboxamidderivater, der er nyttige som cytostatiske og immunosuppressive midler
FR2677028B1 (fr) Nouveaux derives sterouides du pregna-4,9(11),17(20)-trien-3-one.
ITMI930473A1 (it) Derivati idantoinici
IT8864214V0 (it) Porta accendino accessorio promozionale abbigliamento casual e jenseria.
DE29617647U1 (de) Längliches, hohles Bauteil
ITMI913054A0 (it) Fibra cava in poli(2,6-dinetil-p-ossifenilene) modificato